Deep Posterior Post Gluteal Compartment Block in Total Hip Arthroplasty: Feasability and Safety (ANATH)

March 19, 2025 updated by: Yoann ELMALEH, Quincy Anesthésie

Effets D'un Bloc Glutéal Postérieur Profond Associé À Un PENG Bloc Dans La Prothèse Totale De Hanche

This study aims to evaluate the effectiveness of a posterior hip capsule block performed in addition to a PENG (Pericapsular Nerve Group) block for patients undergoing hip arthroplasty. The primary objective is to assess whether this combined approach provides enhanced perioperative analgesia compared to the standard analgesic protocol or the PENG block alone. Secondary outcomes will focus on opioid consumption, functional recovery, and any potential complications. By targeting both the anterior and posterior innervation pathways around the hip joint, this combined technique could improve patient comfort, decrease opioid requirements, and potentially expedite rehabilitation after hip arthroplasty.

Study Overview

Status

Not yet recruiting

Study Type

Interventional

Enrollment (Estimated)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

All adults with total hip arthroplasty

-

Exclusion Criteria:

  • Contraindication to regional anesthesia
  • allergy
  • refusal of the injection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DPPG compartment block
Deep posterior post gluteal compartment block with different volume of product 5,10 and 15 ml (local anesthetics such as naropeine 0.35%) to compare the efficiency of the block without sciatic nerve block effect
One injection with ultrasound guidance injection of 5, 10 or 15 mL of naropeine 0.35 % Procedure : injection below the piriformis muscle in front of the head of the femur.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sciatic nerve block
Time Frame: From enrollment to the end of treatment at 1 month
number of patients with postoperative sciatic motor or sensitory nerve block collected by clinical examination (test with hot and cold in the sciatic territory and motricity of the feet)
From enrollment to the end of treatment at 1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain postoperative
Time Frame: From enrollment to the end of treatment at 1 MONTH
Visual analogic pain (VAS) AT 6 hours 0 : no pain 10: maximum pain
From enrollment to the end of treatment at 1 MONTH
pain 2
Time Frame: From enrollment to the end of treatment at 1 MONTH
Visual analogic pain (VAS) AT 12 hours 0 : no pain 10: maximum pain
From enrollment to the end of treatment at 1 MONTH
oPIOID Consumption
Time Frame: From enrollment to the end of treatment at 7 months
Opioid consumption per and postoperative until 48 hours
From enrollment to the end of treatment at 7 months
RAAC
Time Frame: From enrollment to the end of treatment at 1 MONTH
QOR15 scale at H24 and H48 questionnaire with 15 questions from 0 to 10 (https://pqip.org.uk/FilesUploaded/Myles%20QoR-15.pdf)
From enrollment to the end of treatment at 1 MONTH
Surgical complication
Time Frame: From enrollment to the end of treatment at 1 MONTH
Surgical postoperative complication or fall
From enrollment to the end of treatment at 1 MONTH

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: yoann ELMALEH, M.D, Hôpital Privé Claude Galien

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2025

Primary Completion (Estimated)

February 1, 2026

Study Completion (Estimated)

March 1, 2026

Study Registration Dates

First Submitted

March 13, 2025

First Submitted That Met QC Criteria

March 19, 2025

First Posted (Estimated)

March 26, 2025

Study Record Updates

Last Update Posted (Estimated)

March 26, 2025

Last Update Submitted That Met QC Criteria

March 19, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • COS-RGDS-2024-06-039-P-ELMALEH

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Total Hip Arthroplasty

Clinical Trials on Deep posterior post gluteal nerve block

Subscribe